115 related articles for article (PubMed ID: 23901673)
1. FDG-PET scan in assessing lymphomas and the application of Deauville Criteria.
Awan UE; Siddiqui N; SaadUllah M; Bashir H; Farooqui ZS; Muzaffar N; Mahmmood MT
J Pak Med Assoc; 2013 Jun; 63(6):725-30. PubMed ID: 23901673
[TBL] [Abstract][Full Text] [Related]
2. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale.
Gallamini A; Barrington SF; Biggi A; Chauvie S; Kostakoglu L; Gregianin M; Meignan M; Mikhaeel GN; Loft A; Zaucha JM; Seymour JF; Hofman MS; Rigacci L; Pulsoni A; Coleman M; Dann EJ; Trentin L; Casasnovas O; Rusconi C; Brice P; Bolis S; Viviani S; Salvi F; Luminari S; Hutchings M
Haematologica; 2014 Jun; 99(6):1107-13. PubMed ID: 24658820
[TBL] [Abstract][Full Text] [Related]
3. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of
Isik EG; Kuyumcu S; Kebudi R; Sanli Y; Karakas Z; Cakir FB; Unal SN
Ann Nucl Med; 2017 Nov; 31(9):660-668. PubMed ID: 28741053
[TBL] [Abstract][Full Text] [Related]
4. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
[TBL] [Abstract][Full Text] [Related]
5. International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers.
Biggi A; Gallamini A; Chauvie S; Hutchings M; Kostakoglu L; Gregianin M; Meignan M; Malkowski B; Hofman MS; Barrington SF
J Nucl Med; 2013 May; 54(5):683-90. PubMed ID: 23516309
[TBL] [Abstract][Full Text] [Related]
6. Superscan on 18F-FDG PET-CT imaging for lymphoma: How frequent is it?
Aziz Qureshi PAA; Aleem J; Niazi IK; Hassan A; Bashir H
J Pak Med Assoc; 2022 Sep; 72(9):1845-1847. PubMed ID: 36280989
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas].
Qiao WL; Zhao JH; Wang C; He ZY; Wang TS; Xing Y
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):536-9. PubMed ID: 18069637
[TBL] [Abstract][Full Text] [Related]
8. Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?
Kostakoglu L; Schöder H; Johnson JL; Hall NC; Schwartz LH; Straus DJ; LaCasce AS; Jung SH; Bartlett NL; Canellos GP; Cheson BD;
Leuk Lymphoma; 2012 Nov; 53(11):2143-50. PubMed ID: 22421007
[TBL] [Abstract][Full Text] [Related]
9. [The role of FDG-PET in staging of lymphoma and evaluation of therapeutic efficiency].
Zhou LL; Wang C; Zhao JH; Yan SK; Gao YR; Cai Q; Jiang JL; Wan LP; Yang J; Wei J; Zhao M; Bai HT
Zhonghua Xue Ye Xue Za Zhi; 2009 Apr; 30(4):233-6. PubMed ID: 19731822
[TBL] [Abstract][Full Text] [Related]
10. Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial.
Schmitz C; Rekowski J; Müller SP; Hertenstein B; Franzius C; Ganser A; Bengel FM; Kroschinsky F; Kotzerke J; La Rosée P; Freesmeyer M; Hoeffkes HG; Hertel A; Behringer D; Mesters R; Weckesser M; Mahlmann S; Haberkorn U; Martens U; Prange-Krex G; Brenner W; Giagounidis A; Moeller R; Runde V; Sandmann M; Hautzel H; Wilop S; Krohn T; Dürk H; Heike M; Alashkar F; Brinkmann M; Trenn G; Wacker D; Kreisel-Büstgens C; Bernhard H; Heil G; Larisch R; Kurch L; Jöckel KH; Hoelzer D; Klapper W; Boellaard R; Dührsen U; Hüttmann A
Hematol Oncol; 2020 Aug; 38(3):244-256. PubMed ID: 32067259
[TBL] [Abstract][Full Text] [Related]
11. Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center.
Khong PL; Huang B; Lee EY; Chan WK; Kwong YL
J Nucl Med; 2014 Jun; 55(6):911-6. PubMed ID: 24819420
[TBL] [Abstract][Full Text] [Related]
12. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
[TBL] [Abstract][Full Text] [Related]
13. Direct comparison of 18F-fluorodeoxyglucose coincidence gamma camera tomography with gallium scanning for the staging of lymphoma.
Lin P; Chu J; Kneebone A; Moylan E; Jalaludin B; Pocock N; Kiat H; Rosenfeld D
Intern Med J; 2005 Feb; 35(2):91-6. PubMed ID: 15705137
[TBL] [Abstract][Full Text] [Related]
14. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
[TBL] [Abstract][Full Text] [Related]
15. Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy.
Filippi AR; Piva C; Giunta F; Bellò M; Chiappella A; Caracciolo D; Zotta M; Douroukas A; Ragona R; Vitolo U; Bisi G; Ricardi U
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):311-6. PubMed ID: 23916170
[TBL] [Abstract][Full Text] [Related]
16. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma.
Zinzani PL; Stefoni V; Tani M; Fanti S; Musuraca G; Castellucci P; Marchi E; Fina M; Ambrosini V; Pellegrini C; Alinari L; Derenzini E; Montini G; Broccoli A; Bacci F; Pileri S; Baccarani M
J Clin Oncol; 2009 Apr; 27(11):1781-7. PubMed ID: 19273712
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma.
Zhao J; Qiao W; Wang C; Wang T; Xing Y
Hematology; 2007 Oct; 12(5):423-30. PubMed ID: 17852456
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence.
Isohashi K; Tatsumi M; Higuchi I; Inoue A; Nakajo K; Ishikawa J; Shimosegawa E; Kanakura Y; Nakamura H; Hatazawa J
Ann Nucl Med; 2008 Nov; 22(9):795-802. PubMed ID: 19039558
[TBL] [Abstract][Full Text] [Related]
19. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
20. Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET.
Fanti S; Castellucci P; Stefoni V; Nanni C; Tani M; Rubello D; Ambrosini V; Zinzani PL; Franchi R
Ann Nucl Med; 2008 Jun; 22(5):429-32. PubMed ID: 18600422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]